Latest Commercialisation News

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

Clarity Pharmaceuticals has expanded its breast cancer pipeline by introducing 64/67Cu-SAR-trastuzumab, supported by promising pre-clinical data and a new supply agreement for trastuzumab, aiming to address the unmet needs in HER2-positive breast cancer treatment.

Amaero has completed a A$22 million institutional placement, concluding nearly A$100 million raised since 2022 and positioning itself for commercialisation in FY2026 with a robust balance sheet.

ABx Group and Core Refining have mutually terminated their licence agreement as ABx pivots to a more cost-effective and sustainable method for producing aluminium fluoride, advancing the ALCORE project into its continuous pilot phase in Tasmania.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.

Micro-X has raised $3.3 million through a placement and institutional entitlement offer, reinforcing its strategic shift towards medical imaging technologies. A retail entitlement offer aiming to raise an additional $2.7 million will open shortly, supporting the company’s development of mobile X-ray and CT products.

Nanoveu Limited has completed the strategic acquisition of Embedded A.I. Systems Pte. Ltd. (EMASS), positioning itself at the forefront of ultra-low-power AI-driven edge semiconductor solutions. This move aims to enhance its EyeFly3D™ platform and expand into rapidly growing markets such as wearables, IoT, and autonomous devices.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

PARKD has inked a pivotal five-year exclusive licensing agreement with Fielders, a BlueScope Steel division, to commercialise its innovative MDSB® and MDSS® products in Australia and explore international expansion.

Sparc Technologies has secured a fourth trial agreement with BHP Mitsubishi Alliance to test its graphene-enhanced ecosparc® coating in harsh mining conditions, aiming to validate its anti-corrosive performance against market leaders.